logo-loader
viewArix Bioscience PLC

Arix Bioscience associate talks through current promising coronavirus treatments and vaccines

Arix Bioscience PLC (LON:ARIX) Investment Associate Tim Xu tells Proactive what he believes are promising therapeutics currently being innovated by a variety of biotechs around the word.

Xu, who recently published a blog post entitled "How close are we to a COVID-19 cure? A biotech VC perspective" says he anticipates a potential vaccine to be developed by winter, early spring of 2021, while a treatment, he says, will take a considerably longer time frame.

Quick facts: Arix Bioscience PLC

Price: 85.66 GBX

LSE:ARIX
Market: LSE
Market Cap: £116.16 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience PLC: Proactive One2One Virtual Event

Arix Bioscience PLC's (LON:ARIX) Jonathan Tobin pitches the company to investors at the Proactive One2One Virtual Event. Arix is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

3 weeks, 5 days ago

2 min read